Acarbose in the Treatment of Chronic Renal Disease

Probably systemic atherosclerosis is the main cause of aging and death. Methods: All patients with sickle cell diseases (SCD) were taken into the study. Results: We studied 222 males and 212 females with mean ages of 30.8 vs 30.3 years, p>0.05, respectively. Smoking (23.8% vs 6.1%, p<0.001), alcohol (4.9% vs 0.4%, p<0.001), transfused red blood cells (RBC) in their lifespans (48.1 vs 28.5 units, p=0.000), disseminated teeth losses (5.4% vs 1.4%, p<0.001), ileus (7.2% vs 1.4%, p<0.001), chronic renal disease (CRD) (9.9% vs 6.1%, p<0.05), cirrhosis (8.1% vs 1.8%, p<0.001), chronic obstructive pulmonary disease (25.2% vs 7.0%, p<0.001), coronary heart disease (18.0% vs 13.2%, p<0.05), leg ulcers (19.8% vs 7.0%, p<0.001), digital clubbing (14.8% vs 6.6%, p<0.001), and stroke (12.1% vs 7.5%, p<0.05) were all higher in males, significantly. Conclusion: As an accelerated systemic atherosclerotic process, hardened RBC-induced capillary endothelial damage initiated at birth terminates with multiorgan failures in early decades of life in the SCD. Excess fat tissue may be much more significant than smoking and alcohol for atherosclerosis since excess weight-induced diabetes mellitus is the most common cause of the CRD. The efficacy of acarbose to lower blood glucose by preventing breakdown of starch into sugar in the small intestine is obvious. Because acarbose is a safe, cheap, oral, long-term used, and effective drug for excess weight, it should be prescribed even in the CRD since there are nearly 33 kg of excess fat tissue even between the lower borders of normal weight and obesity in adults.